Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

Anas Younes, MD
Published Online: Thursday, August 28, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.

Online CME Activities
Free CME from PER
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
More Reading
Publications
$auto_registration$